Recessive dystrophic epidermolysis bullosa inversa

disease
On this page

Also known as dystrophic epidermolysis bullosa inversainverse RDEBinverse recessive dystrophic epidermolysis bullosaRDEB-I

Summary

Recessive dystrophic epidermolysis bullosa inversa (MONDO:0019310) is a disease with 1 cohort gene.

At a glance

  • Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
  • Cohort genes: 1
  • Phenotypes (HPO): 28

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Cases/families100WorldwideValidated
Point prevalence<1 / 1 000 000WorldwideValidated

Signs & symptoms

Clinical features (HPO)

28 HPO clinical features (Orphanet curated; top 28 by frequency):

HPO IDTermFrequency
HP:0001030Fragile skinVery frequent (80-99%)
HP:0000079Abnormality of the urinary systemFrequent (30-79%)
HP:0000670Carious teethFrequent (30-79%)
HP:0001056MiliaFrequent (30-79%)
HP:0001075Atrophic scarsFrequent (30-79%)
HP:0001798AnonychiaFrequent (30-79%)
HP:0004386Gastrointestinal inflammationFrequent (30-79%)
HP:0008066Abnormal blistering of the skinFrequent (30-79%)
HP:0008404Nail dystrophyFrequent (30-79%)
HP:0011355Localized skin lesionFrequent (30-79%)
HP:0031464Genital blisteringFrequent (30-79%)
HP:0200097Oral mucosal blistersFrequent (30-79%)
HP:0000402Stenosis of the external auditory canalOccasional (5-29%)
HP:0001510Growth delayOccasional (5-29%)
HP:0001903AnemiaOccasional (5-29%)
HP:0002043Esophageal strictureOccasional (5-29%)
HP:0004057Mitten deformityOccasional (5-29%)
HP:0007446Palmoplantar blisteringOccasional (5-29%)
HP:0012227Urethral strictureOccasional (5-29%)
HP:0025416Vaginal strictureOccasional (5-29%)
HP:0000478Abnormality of the eyeExcluded (0%)
HP:0000982Palmoplantar keratodermaExcluded (0%)
HP:0001965Abnormality of the scalpExcluded (0%)
HP:0002671Basal cell carcinomaExcluded (0%)
HP:0002860Squamous cell carcinomaExcluded (0%)
HP:0006297Enamel hypoplasiaExcluded (0%)
HP:0012056Cutaneous melanomaExcluded (0%)
HP:0012252Abnormal respiratory system morphologyExcluded (0%)

Identifiers

Disease identifiers

FieldValue
Canonical namerecessive dystrophic epidermolysis bullosa inversa
Mondo IDMONDO:0019310
Orphanet79409
ICD-11495465277
UMLSC1275113
MedGen698413
GARD0016720
Is cancer (heuristic)no

Also known as: dystrophic epidermolysis bullosa inversa · inverse RDEB · inverse recessive dystrophic epidermolysis bullosa · RDEB-I

Data availability: 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disordervesiculobullous skin diseaseepidermolysis bullosainherited epidermolysis bullosaepidermolysis bullosa dystrophicarecessive dystrophic epidermolysis bullosarecessive dystrophic epidermolysis bullosa inversa

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 26 · Orphanet: 9 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
COL7A1DefinitiveAutosomal recessiverecessive dystrophic epidermolysis bullosa26

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
COL7A1Orphanet:158673Localized dystrophic epidermolysis bullosa, acral form
COL7A1Orphanet:158676Localized dystrophic epidermolysis bullosa, nails only
COL7A1Orphanet:231568Autosomal dominant generalized dystrophic epidermolysis bullosa
COL7A1Orphanet:79408Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form
COL7A1Orphanet:79409Recessive dystrophic epidermolysis bullosa inversa
COL7A1Orphanet:79410Localized dystrophic epidermolysis bullosa, pretibial form
COL7A1Orphanet:79411Self-improving dystrophic epidermolysis bullosa
COL7A1Orphanet:89842Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form
COL7A1Orphanet:89843Dystrophic epidermolysis bullosa pruriginosa

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
COL7A1HGNC:2214ENSG00000114270Q02388Collagen alpha-1(VII) chaingencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
COL7A1Collagen alpha-1(VII) chainStratified squamous epithelial basement membrane protein that forms anchoring fibrils which may contribute to epithelial basement membrane organization and adherence by interacting with extracellular matrix (ECM) proteins such as type IV c…

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Antibody/Immunoglobulin129.2×0.034

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
COL7A1Antibody/ImmunoglobulinyesVWF_A, Kunitz_BPTI, FN3_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
skin of abdomen1
skin of leg1
stromal cell of endometrium1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
COL7A1267ubiquitousmarkerstromal cell of endometrium, skin of abdomen, skin of leg

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
COL7A11,767

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
COL7A1Q02388

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 10. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Anchoring fibril formation1761.3×0.007COL7A1
Fibronectin matrix formation1571.0×0.007COL7A1
Laminin interactions1380.7×0.007COL7A1
Cargo concentration in the ER1335.9×0.007COL7A1
Collagen chain trimerization1259.6×0.007COL7A1
Assembly of collagen fibrils and other multimeric structures1200.3×0.007COL7A1
Collagen degradation1175.7×0.007COL7A1
Collagen biosynthesis and modifying enzymes1170.4×0.007COL7A1
COPII-mediated vesicle transport1163.1×0.007COL7A1
Integrin cell surface interactions1134.3×0.007COL7A1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
endodermal cell differentiation1495.6×0.006COL7A1
epidermis development1210.7×0.007COL7A1
cell adhesion137.5×0.027COL7A1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
COL7A100

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug1COL7A1
EDifficult family or no structure, no drug0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
COL7A10

Clinical trials & evidence

Clinical trials

Clinical trials: 0.